Olema Pharmaceuticals, Inc. (OLMA) SEC Filings

Olema Pharmaceuticals, Inc. filed an initial statement of beneficial ownership for its Chief Financial Officer, Jason O'Byrne. The filing reports no equity transactions and shows no reported holdings or derivative positions at this time.

Olema Pharmaceuticals appointed Jason O’Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 11, 2026. He brings more than two decades of finance leadership in biotechnology and pharmaceuticals, including CFO roles at Vir Biotechnology and Caribou Biosciences and senior finance positions at Audentes Therapeutics, Genentech and Roche.

Under his offer letter, O’Byrne will receive a $545,000 annual base salary, a target bonus equal to 45% of base salary, and sign-on bonuses totaling $350,000, subject to service-based repayment obligations. Subject to Board approval, he will receive an option to purchase 650,000 shares of common stock under Olema’s 2022 Inducement Plan, vesting over four years.

If terminated without Cause or if he resigns for Good Reason, including in connection with a Change in Control, he is eligible for severance benefits that may include up to 12 months of salary, target bonus, prorated bonus, equity vesting acceleration, and up to 12 months of COBRA premium reimbursement.

Olema Pharmaceuticals, Inc., a clinical-stage oncology company, reported a larger net loss while maintaining a substantial cash position for the six months ended June 30, 2026. Total operating expenses rose to $125.2 million from $82.7 million a year earlier, driven primarily by increased research and development spending of $107.0 million and higher general and administrative costs of $18.1 million. Net loss widened to $116.3 million compared with $74.2 million in the prior-year period, or $1.12 per share versus $0.87.

The company generated $9.3 million of interest income from its investment portfolio. Cash used in operating activities was $91.9 million in the first half of 2026, partially offset by $45.4 million provided by investing activities and $46.8 million from financing, including $41.9 million of net proceeds from an at-the-market equity offering. As of June 30, 2026, Olema held $461.2 million in cash, cash equivalents and marketable securities and reported management’s view that these resources, together with available borrowing capacity, are sufficient to fund the current operating plan for at least 12 months from the reporting date.

Olema continues to advance its lead ER-targeted therapy palazestrant (OP-1250) and KAT6 inhibitor OP-3136, supported by multiple collaboration and supply agreements with Novartis and Pfizer. The company also expanded its facilities footprint with new long-term leases for future headquarters and additional office space, adding fixed lease commitments while existing short-term lease liabilities declined.

Olema Oncology (Olema Pharmaceuticals, Inc.) reported second quarter 2026 results and key pipeline milestones. Enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant in ER+/HER2- metastatic breast cancer is complete, with top-line data now expected in the first quarter of 2027. Enrollment is advancing in the OPERA-02 Phase 3 combination trial with ribociclib and in multiple Phase 1/2 combination studies. Initial Phase 1 monotherapy data for KAT6 inhibitor OP-3136 showed it was well-tolerated with evidence of anti-tumor activity, and a new collaboration with Bayer will evaluate OP-3136 plus darolutamide in metastatic castration-resistant prostate cancer.

Olema ended June 30, 2026 with $461.1 million in cash, cash equivalents, and marketable securities. Net loss for the quarter was $63.2 million versus $43.8 million a year earlier, driven mainly by higher clinical and corporate spending to support late-stage trials and commercialization planning. GAAP R&D expense was $57.8 million and GAAP G&A was $9.4 million; on a non-GAAP basis, excluding stock-based compensation, R&D was $48.9 million and G&A was $5.4 million.

Olema Pharmaceuticals Inc. large shareholder filing: FMR LLC filed Amendment No. 2 to a Schedule 13G reporting beneficial ownership of 12,075,061.72 shares of Olema Pharmaceuticals Inc. common stock, representing 13.8% of the class as of June 30, 2026.

FMR LLC reports sole dispositive power over 12,075,061.72 shares and sole voting power over 12,074,535 shares, with no shared voting or dispositive power. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over 12,075,061.72 shares. One or more other persons have rights to dividends or sale proceeds for these shares, but no such person holds an interest exceeding five percent of the outstanding common stock.

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of Olema Pharmaceuticals, Inc. as of June 30, 2026. BlackRock reported beneficial ownership of 6,244,212 shares of Olema common stock, representing 7.1% of the outstanding class.

BlackRock reported sole voting power6,138,842 shares and sole dispositive power6,244,212 shares, with no shared voting or dispositive power. Various underlying clients and investors may have rights to dividends and sale proceeds, but no single person is reported to hold more than five percent of Olema’s outstanding common shares through these holdings.

Olema Pharmaceuticals director Cyrus Harmon reported selling a total of 25,000 shares of common stock in open-market or private transactions on July 23 and 24, 2026, at weighted average prices of $11.579 and $11.714 per share, respectively. An additional 117,028 shares are reported as held indirectly by Harmon Family Investors LLC, where Harmon is the manager.

Cyrus L. Harmon filed to sell 12,500 common shares of OLMA through Fidelity Brokerage Services LLC on July 24, 2026 on NASDAQ, with an indicated value of $146,419.49. The filing also reports that Harmon sold 12,500 common shares on July 23, 2026 for $144,737.53, originally acquired as founders shares on March 20, 2007 as compensation.